Aclarion (ACON) Stock Price

Aclarion Price

NYSE·CLOSED
2.38
​
Market closed

Revenue has compounded at 18.8% per year over the past 6 years to 75,730.00 USD. Aclarion's net margin stands at -9,551.9%, down from -8,210.5% several years earlier. Analysts set a median price target of 1.33 USD, implying 44.3% below the current price. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.

Aclarion stock price

Access this data via the Eulerpool API

Aclarion business model & stock analysis

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 7 full-time employees. The company went IPO on 2022-04-22. The Company’s signal processing software and expert system transform raw spectral MRS data into clear metabolic biomarkers to help physicians determine between painful and nonpainful discs of the lumbar spine. The firm is using augmented intelligence in a post-processing algorithm to analyze and quantifies the biomarker data, generating ratio metrics for each lumbar disc that are individualized to a normative data set. The Company’s technology is focused on the care of patients suffering from chronic low back pain.

Frequently asked questions about Aclarion

Analysts currently set an average price target of 1.33 USD for the Aclarion stock (median: 1.33 USD), implying -44.3 % versus the latest price. The consensus is based on 8 analyst ratings.

7 analysts currently rate the Aclarion stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Aclarion to generate revenue of 135,000.00 USD and earnings per share of -0.01 USD.

Converted at the current exchange rate, the Aclarion share trades at 2.13 EUR (2.38 USD).

The expected revenue of Aclarion is 135,000.00 USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Aclarion is -4,059.00 USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Aclarion is currently -311.94. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Aclarion stock.

The price-to-sales ratio (P/S) of Aclarion is currently 9.38. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Aclarion stock.

The Eulerpool Quality Score for Aclarion is 3/10.

The ISIN of Aclarion is US6551874091. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Aclarion is ACON. The ticker symbol is used to trade Aclarion shares on the stock exchange.

Fair ValueTerminal
2.14 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Technology
Number of shares
Employees
Revenue per Employee
10,818.57 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website aclarion.com
Currency
USD
Initial public offering
Apr 22, 2022
ISIN
US6551874091
Cusip
655187102
Market capitalization
2,142.00 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-311.94
P/Ee 2027
-257.19
P/Se
9.38
EV/EBIT
—
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-56.36 %
Last updated Oct 8, 2026, 5:16 PM

Aclarion Peer Group

All fundamentals and in-depth analysis of Aclarion

Our stock analysis for Aclarion stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aclarion. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.